Sort   by:  
 Page size 
UnknownResistance to Gemcitabine in Pancreatic Cancer Is Connected to Methylglyoxal Stress and Heat Shock Response.
Not available
S-EPMC10217245 | biostudies-literature
UnknownNovel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?
Not available
S-EPMC7343368 | biostudies-literature
UnknownIsotoxic High-Dose Stereotactic Body Radiotherapy (iHD-SBRT) Versus Conventional Chemoradiotherapy for Localized Pancreatic Cancer: A Single Cancer Center Evaluation.
Not available
S-EPMC9741086 | biostudies-literature
UnknownCombination, Modulation and Interplay of Modern Radiotherapy with the Tumor Microenvironment and Targeted Therapies in Pancreatic Cancer: Which Candidates to Boost Radiotherapy?
Not available
S-EPMC9913158 | biostudies-literature
UnknownPreoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial.
Not available
S-EPMC10512504 | biostudies-literature
UnknownClinical application of targeted next-generation sequencing for colorectal cancer patients: a multicentric Belgian experience.
Not available
S-EPMC5945518 | biostudies-literature
UnknownIsotoxic high-dose stereotactic body radiotherapy integrated in a total multimodal neoadjuvant strategy for the treatment of localized pancreatic ductal adenocarcinoma.
Not available
S-EPMC8529314 | biostudies-literature
UnknownImpact of the radiological morphology of the mesopancreas on the outcome after pancreatoduodenectomy for pancreatic ductal adenocarcinoma: retrospective study.
Not available
S-EPMC11599710 | biostudies-literature
UnknownPancreatic medullary carcinoma developed on a pancreatic intraductal papillary mucinous neoplasm with loss of MSH2 and MSH6 expression: a case report.
Not available
S-EPMC8667442 | biostudies-literature
UnknownPositron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas.
Not available
S-EPMC4803456 | biostudies-literature
Sort   by:  
 Page size